Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. - Wikidata - wikimedia - TriplyDB

Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury.

Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury.

http://www.wikidata.org/entity/Q45246407

about

Nebulized PPARγ agonists: a novel approach to augment neonatal lung maturation and injury repair in rats Effect of salidroside on lung injury by upregulating peroxisome proliferator-activated receptor γ expression in septic rats.Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules.Innovative approaches to the therapy of fibrosis Efficacies of rosiglitazone and retinoin on bleomycin-induced pulmonary fibrosis in rats.Serial micro-CT assessment of the therapeutic effects of rosiglitazone in a bleomycin-induced lung fibrosis mouse model.Nrf2-regulated PPAR{gamma} expression is critical to protection against acute lung injury in mice Peroxisome proliferator-activated receptor gamma agonists enhance lung maturation in a neonatal rat model.Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease.Troglitazone attenuates TGF-β1-induced EMT in alveolar epithelial cells via a PPARγ-independent mechanism.Involvement of PPAR nuclear receptors in tissue injury and wound repair Endogenous lipid mediators in the resolution of airway inflammation Relaxin activates peroxisome proliferator-activated receptor γ (PPARγ) through a pathway involving PPARγ coactivator 1α (PGC1α)Integrating mechanisms of pulmonary fibrosis Carbon-nanoparticle-triggered acute lung inflammation and its resolution are not altered in PPARγ-defective (P465L) mice.The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects.Estrogenic modulation of inflammation-related genes in male rats following volume overload Airway epithelial cell PPARγ modulates cigarette smoke-induced chemokine expression and emphysema susceptibility in mice.The Role of PPARs in Lung Fibrosis.Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases.Postnatal rosiglitazone administration to neonatal rat pups does not alter the young adult metabolic phenotype.Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis.Prenatal rosiglitazone administration to neonatal rat pups does not alter the adult metabolic phenotype.Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?PPARγ activation following apoptotic cell instillation promotes resolution of lung inflammation and fibrosis via regulation of efferocytosis and proresolving cytokines.Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease.Anti-inflammatory role of PGD2 in acute lung inflammation and therapeutic application of its signal enhancement.15-deoxy-delta12,14-prostaglandin J2 attenuates endothelial-monocyte interaction: implication for inflammatory diseases The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator.Transforming growth factor beta as a therapeutic target in systemic sclerosis.Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease.Diabetes, insulin, and development of acute lung injury.Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury.Targeted therapies for systemic sclerosis.Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts.The Role of PPAR Gamma in Systemic Sclerosis.Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis.Novel Anti-fibrotic Therapies.

P2860

Q33594612-D4B3450C-02DD-412F-8D2B-ADF6DC3DF92C Q33706195-E8EC0B80-EABC-484C-BE9E-64172B4E1552 Q33799573-0B9EC6ED-B110-4DCB-A505-BBF50FDB60AF Q33824140-FFEF0168-6425-402F-BD59-B173330CCA89 Q33847144-2EE7BA84-062E-4A0C-8208-3DA5CE9F6098 Q33929299-BAC3F5D2-F317-4717-AFBF-9BA7DC3A7503 Q34032853-B667A7C1-14FB-4441-9E36-44B275014FC2 Q34064187-5B46E99A-DEE4-448E-BB81-6CE21DF281DC Q34260759-244EFC2C-9F23-4160-BDAA-B480C60F180A Q34321160-D660F541-BEE0-4F6C-B331-F4550EC356D6 Q34416422-84520D08-4E9E-4096-BE11-D75EFDA2F7D2 Q34423359-618966C0-E00A-4B6F-84BA-EDD2FF6A8C58 Q34958919-70146274-03FA-4042-9FB1-7D320B56B42F Q35106452-55979D20-C6B8-4107-8174-40FF7F370461 Q35397274-1691F945-314C-4CDB-877A-DC94F6FA6C15 Q35503543-E4480F5C-A765-4EEB-A604-3E4981A82400 Q35890923-CA19EBF2-31E0-4E57-8BCF-15C6055C7F2B Q35916876-7D6C0348-5C76-43DF-B1AF-11F261F1FDFA Q35925362-9E66FB1D-A555-4413-BA98-4D73B08F98E5 Q36063833-9F1EAF59-AD24-4FD1-92EA-F3DFB7E6F37B Q36072086-26B24044-1F38-4624-881F-21C89AA475A5 Q36093802-A5E7D060-C76D-4BFC-BEB8-0EE1822BD8ED Q36100056-B27481C2-CB73-4963-86D9-407E6C948027 Q36443665-7BFF42DD-C6CF-41BD-9831-91CF6089AFD9 Q36591722-AE1CF2F3-6E24-41BE-8764-E9A2A5A77468 Q36605155-983CC859-FB28-4F6C-97D8-F2C5140887EB Q36687379-8641BA68-4F24-46FC-BC26-4E2886C88307 Q36729601-877C5AE9-F789-41E9-803C-EFE51EC7A837 Q36865438-B789D8D3-5B21-46C0-9BA5-8766A11CC309 Q36970923-6BBCBB8F-73FE-4C82-9B59-4867A0AFEBE9 Q37326935-8E198587-F0E3-4913-A556-D12A1A8BF8FB Q37428739-FD6056FA-17BC-4B7D-A97F-997FCCED2A22 Q37447470-BAFC3755-FD3F-4057-98B4-1DB8917ABF33 Q37521491-A69C0D01-ABEB-4EAC-9C93-D1D65B379F23 Q37899155-18A55CCA-26B5-4126-9252-49645C812E78 Q38097276-B7730D2F-7AFA-4ECD-9429-0D34B5ED691F Q38355897-A079641E-C6D0-4F8B-8298-C6AE6645AC00 Q38524619-DBF957D0-A3F6-4B3F-BF0E-090AC623A6E8 Q39170625-A5D0C420-785F-4182-894C-39DB2A94A685 Q39377055-5E874ED2-3C57-45C7-AC92-E06E5FE02F9D

P2860

Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury.

http://www.wikidata.org/entity/Q45246407

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Effect of rosiglitazone and 15 ...... bleomycin-induced lung injury.

@en

Effect of rosiglitazone and 15 ...... bleomycin-induced lung injury.

@nl

type

label

Effect of rosiglitazone and 15 ...... bleomycin-induced lung injury.

@en

Effect of rosiglitazone and 15 ...... bleomycin-induced lung injury.

@nl

prefLabel

Effect of rosiglitazone and 15 ...... bleomycin-induced lung injury.

@en

Effect of rosiglitazone and 15 ...... bleomycin-induced lung injury.

@nl

P1433

Q45246407-53EE4EE2-5481-4C05-90C1-8F66D7F31080

P1476

Q45246407-15FA9089-6F8B-46BC-93D7-17D16FDA46C7

P2093

Q45246407-209019C9-D586-4846-B246-680C76E6429B

Q45246407-5E34E679-0266-449A-8D8D-71073A337151

Q45246407-69698762-7D55-4C60-B8ED-88871E3778F4

Q45246407-7AC55356-8174-4BD9-BCBD-E6C71F98E1B1

Q45246407-7D6BD613-B381-4A0E-B6A6-ABB1AE4E140E

Q45246407-839ED753-25B9-4EDB-A2C0-3D85164B9C1E

Q45246407-87F91B19-35D6-4BC0-8BD7-700913F1A4A2

Q45246407-9C5928CD-8907-426A-AF06-F175B8518CB7

Q45246407-BD1E3D3C-02D7-4203-98CA-85748E6C9335

Q45246407-F7C67CD6-48B7-410A-AD8E-7C3FA765577F

P304

Q45246407-6C89103E-2A82-44BA-93C1-879DC78260FC

P31

Q45246407-A30D33AA-C357-463E-B04C-D07540E8E068

P356

Q45246407-0452E029-D135-4154-B595-B48EBD7B8606

P433

Q45246407-583147F2-14B6-4C54-B406-F5EC124FDA4B

P478

Q45246407-602A0C0E-230F-45C5-B3ED-1D57AC99A7F7

P50

Q45246407-26420A64-A17E-43DE-A1B7-25CA86B382F8

P577

Q45246407-0362A849-08DB-4424-9C26-DDDD3F4F5D0F

P5875

Q45246407-DFE78587-5980-4FB0-80C9-391565AB9EBD

P698

Q45246407-7FFF414E-49C5-4CEE-9470-0C8E145420EE

P356

09031936.05.00049704

P1433

European Respiratory Journal

P1476

Effect of rosiglitazone and 15 ...... bleomycin-induced lung injury.

@en

P2093

A P Caputi

http://www.w3.org/2001/XMLSchema#string

C Mastruzzo

http://www.w3.org/2001/XMLSchema#string

C Thiemermann

http://www.w3.org/2001/XMLSchema#string

C Vancheri

http://www.w3.org/2001/XMLSchema#string

E Mazzon

http://www.w3.org/2001/XMLSchema#string

M Sortino

http://www.w3.org/2001/XMLSchema#string

P Catalano

http://www.w3.org/2001/XMLSchema#string

R Di Paola

http://www.w3.org/2001/XMLSchema#string

S Cuzzocrea

http://www.w3.org/2001/XMLSchema#string

T Genovese

http://www.w3.org/2001/XMLSchema#string

P304

225-234

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1183/09031936.05.00049704

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8048642

http://www.w3.org/2001/XMLSchema#string

P698

15684285

http://www.w3.org/2001/XMLSchema#string